Navigation Links
Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye
Date:11/10/2008

LAWRENCEVILLE, N.J., Nov. 10 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced results of a recent survey of ophthalmologists regarding issues in the treatment of moderate to severe cases of dry eye. Aton provides the dry eye medication Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert), a preservative-free, once-daily*, sustained release prescription insert that helps to retain moisture, stabilize the tear film, and lubricate the eye.

Nearly all of the ophthalmologists surveyed (94%) believe more treatment options are needed for moderate to severe dry eye. While 80% feel current therapies are effective for mild dry eye, only 33% feel they are effective for moderate dry eye and 67% feel they are only somewhat effective or not very effective. Only 5% feel current therapies are effective for severe dry eye, while 56% feel they are somewhat effective and 38%, not very or not at all effective.

"Ophthalmologists are still looking for more effective therapies for treating moderate to severe dry eye," commented Dr. Penny Asbell, Professor, Department of Ophthalmology, Mount Sinai School of Medicine; Director, Cornea Services and Refractive Surgery Center, New York; and co-author of the pivotal textbook 'Dry Eye Disease, the Clinician's Guide to Diagnosis and Treatment.' "Nearly all ophthalmologists want more treatment options for these more serious cases." Dr. Asbell is a member of Aton Pharma's Scientific Advisory Board.

"We are proud to be working with Dr. Asbell to contribute to eye care professionals' insights about the state of the art of treatment of dry eye," stated Michael G. Wells, Chief Executive Officer of Aton Pharma. "Ophthalmology is one of the important markets Aton serves as a diversified specialty pharmaceutical company providing medically essential therapies to patients around the world."

Treatment Approaches and Options

The survey respondents reported that over the
'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Survey: 90% of Participating Surgeons Report Syndicom SpineConnect Improves Practice of Spine Surgery
2. AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Companys Prescription Savings Programs
3. Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
10. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... 2015 , ... Global Resorcinol Market 2015-2019 is a comprehensive ... global resorcinol industry. The report highlights the various growth prospects and the prevalent ... of primary and secondary inputs from the existing players of the resorcinol market. ...
(Date:7/30/2015)... July 30, 2015   GenoSpace , a ... interpretation and analysis of genomic and other biomedical ... has joined the company as Vice President of ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners with ... interpret, analyze and explore complex sets of genomic, ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, Inc. ... has received the second $1.0M tranche under a ... (SBIR) grant valued at up to $3.0 million ... KL4 surfactant as a potential medical countermeasure to ... Labs was awarded an initial $1.0 million under ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... ... ... -- Professor Jean M. J. Frchet, a pioneering chemist who has achieved great success ... King Abdullah University of Science and Technology (KAUST) in Saudi Arabia., , , , ...
... ... American Communications Professionals Honors LaVoie Group for Best Industry-Exclusive Agency and Best Business ... ... Group , a life science and pharmaceuticals focused strategic communications agency, announced today ...
... , ... a life science-focused strategic communications agency, announced today that it has been selected by ... develop and execute its corporate communications and public relations program. , ... Salem, MA (Vocus) February 8, 2010 ...
Cached Biology Technology:Frchet Named Vice President for Research at Kaust 2Frchet Named Vice President for Research at Kaust 3Frchet Named Vice President for Research at Kaust 4Frchet Named Vice President for Research at Kaust 5LaVoie Group Honored by LACP with Two Awards 2LaVoie Group Honored by LACP with Two Awards 3LaVoie Group Honored by LACP with Two Awards 4Invida Selects LaVoie Group as Public Relations Agency of Record 2Invida Selects LaVoie Group as Public Relations Agency of Record 3
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... release is available in German . ... strategy for the individual but it can drive the species ... Daniel Rankin from the University of Zurich has demonstrated in ... long debated whether the behavior of the individual is able ...
... Monday, May 16, 2011 A new discovery in mice ... day allow doctors to spare some patients with acute myeloid ... for new therapeutic research. AML, the most common ... form of cancer that primarily affects the elderly. Despite years ...
... Packard and the University of California, Santa Barbara, have ... of an electronic device that computer engineers hope will ... memory resistors, are a newly understood circuit element for ... seek ways of mimicking the behaviour of our own ...
Cached Biology News:Aggressive male mating behavior can endanger species 2Study reveals need for personalized approach in treatment of AML 2Study reveals need for personalized approach in treatment of AML 3'Computer synapse' analyzed at the nanoscale 2